share_log

CbdMD (NYSEAMERICAN:YCBD) Shares Down 3.5%

CbdMD (NYSEAMERICAN:YCBD) Shares Down 3.5%

美國加拿大紐約證券交易所股價下跌 3.5%
Financial News Live ·  2022/12/23 01:01

cbdMD, Inc. (NYSEAMERICAN:YCBD – Get Rating) shares were down 3.5% during trading on Thursday . The stock traded as low as $0.24 and last traded at $0.25. Approximately 119,448 shares traded hands during trading, a decline of 55% from the average daily volume of 267,845 shares. The stock had previously closed at $0.26.

CbdMD,Inc.(NYSEAMERICAN:YCBD-GET Rating)股價週四下跌3.5%。該股最低交易價格為0.24美元,最新報0.25美元。約119,448股股票在交易中成交,較267,845股的日均成交量下降了55%。該股此前收盤價為0.26美元。

cbdMD Stock Performance

CbdMD股票表現

The firm has a market capitalization of $15.17 million, a P/E ratio of -0.24 and a beta of 2.00.

該公司的市值為1517萬美元,本益比為-0.24,貝塔係數為2.00。

Get
到達
cbdMD
CbdMD
alerts:
警報:

Institutional Trading of cbdMD

Cbdmd的機構交易

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. bought a new stake in cbdMD during the second quarter worth $32,000. Renaissance Technologies LLC raised its position in shares of cbdMD by 49.3% in the first quarter. Renaissance Technologies LLC now owns 93,600 shares of the company's stock valued at $97,000 after purchasing an additional 30,900 shares during the period. Vident Investment Advisory LLC raised its position in shares of cbdMD by 68.4% in the first quarter. Vident Investment Advisory LLC now owns 119,283 shares of the company's stock valued at $124,000 after purchasing an additional 48,470 shares during the period. ExodusPoint Capital Management LP bought a new position in shares of cbdMD in the third quarter valued at about $32,000. Finally, Cambria Investment Management L.P. raised its position in shares of cbdMD by 23.4% in the third quarter. Cambria Investment Management L.P. now owns 286,254 shares of the company's stock valued at $64,000 after purchasing an additional 54,214 shares during the period. 41.08% of the stock is owned by institutional investors.

機構投資者和對沖基金最近增持或減持了該公司的股份。保誠金融在第二季度購入了價值3.2萬美元的cbdMD新股份。復興科技有限責任公司在第一季度將其在cbdMD的股票頭寸增加了49.3%。復興科技有限責任公司在此期間又購買了30,900股,現在擁有93,600股該公司的股票,價值97,000美元。維登特投資諮詢有限責任公司在第一季度將其在cbdmd股票的持倉增加了68.4%。在此期間又購買了48,470股後,Viden Investment Consulting LLC現在擁有119,283股該公司的股票,價值12.4萬美元。ExodusPoint Capital Management LP在第三季度購買了cbdMD的新頭寸,價值約3.2萬美元。最後,Cambria Investment Management L.P.在第三季度將其在cbdMD的股票頭寸提高了23.4%。Cambria Investment Management L.P.在此期間又購買了54,214股,現在擁有286,254股該公司的股票,價值64,000美元。41.08%的股份由機構投資者持有。

cbdMD Company Profile

CbdMD公司簡介

(Get Rating)
(獲取評級)

cbdMD, Inc produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name.

CbdMD,Inc.生產和分銷各種大麻二醇(CBD)產品。該公司擁有和經營以大麻為基礎的消費CBD品牌,如cbdMD、Paw CBD和cbdMD Botanals。其cbdMD品牌產品包括CDB酊劑、口香糖、外用藥物、膠囊、沐浴炸彈、浴鹽和助眠藥。它還提供獸醫配方的產品,包括酊劑、口香糖和Paw CBD品牌下的外用藥物。

Read More

閱讀更多內容

  • Get a free copy of the StockNews.com research report on cbdMD (YCBD)
  • Are Caterpillar and Deere Setting Up to Rally in 2023?
  • Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
  • Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
  • Lucid Motors Faces a Reality That May Cloud a Bullish Perception
  • Institutions Put Bottom In Rite Aid Shares
  • 免費獲取StockNews.com關於cbdMD(YCBD)的研究報告
  • 卡特彼勒和迪爾準備在2023年重整旗鼓嗎?
  • 馬倫汽車公司在i-Go登陸歐洲之際受到震動
  • 2023年,太陽會照耀這3只大盤太陽能股嗎?
  • Lucid Motors面臨的現實可能會給看漲的看法蒙上陰影
  • 機構將Rite Aid的股票跌至谷底

Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.

接受cbdMD日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對cbdMD和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論